Document is current
Any future updates will be listed below
-
Authors
Liva, Sophia G
Tseng, Yu‐Chou
Dauki, Anees M
Sovic, Michael G
Vu, Trang
Henderson, Sally E
Kuo, Yi‐Chiu
Benedict, Jason A
Zhang, Xiaoli
Remaily, Bryan C
Kulp, Samuel K
Campbell, Moray
Bekaii‐Saab, Tanios
Phelps, Mitchell A
Chen, Ching‐Shih
Coss, Christopher C https://orcid.org/0000-0002-8184-9190
-
Funding
Funding for this research was provided by:
HHS|NIH|Office of Extramural Research, National Institutes of Health (K12‐CA133250‐07)
OSUCCC Pelotonia Idea Award
Eli Lilly Fellowship
- License Information
-
More Information
Article History
Received: 14 October 2018
Revised: 26 November 2019
Accepted: 29 November 2019
First Online: 13 January 2020
Conflict of interest
: C.‐S. Chen is an inventor of AR‐42, which was licensed to Recursion Pharmaceuticals, Inc., for clinical development by The Ohio State University Research Foundation. C.C. Coss is a former employee of GTx, Inc., owner of GTx‐024, but has no financial relationship with or any equity in GTx, Inc. Recursion Pharmaceuticals, Inc. and GTx, Inc. were not involved in any way with the financing, design, or interpretation of the reported studies. All other authors declare that they have no conflict of interest.
